Modelling the influence of MDR1 polymorphism on digoxin pharmacokinetic parameters

European Journal of Clinical Pharmacology

Volumn 63, Issue 5, 2007, Pages 437-449

  Comets, Emmanuelle ^a,b   Verstuyft, Céline ^c,d   Lavielle, Marc ^b,d   Jaillon, Patrice ^e,g   Becquemont, Laurent ^c,d,f   Mentré, France ^a,b,f  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c BICÊTRE HOSPITAL   (France)

^d UNIVERSITÉ PARIS SACLAY   (France)

^e SORBONNE UNIVERSITÉ   (France)

^f ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^g HÔPITAL SAINT ANTOINE   (France)

Author keywords

Digoxin; P glycoprotein; Pharmacogenetics; Population pharmacokinetics

Indexed keywords

DIGOXIN; GLYCOPROTEIN P; MULTI DRUG RESISTANCE 1 PROTEIN; PROTEIN DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; ALLELE; ARTICLE; ASSAY; BAYES THEOREM; BLOOD SAMPLING; COVARIANCE; DISTRIBUTION VOLUME; DRUG BIOAVAILABILITY; EXON; FEMALE; GENETIC CODE; GENOTYPE; HETEROZYGOTE; HUMAN; MALE; MODEL; NONLINEAR SYSTEM; PARAMETER; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; STOCHASTIC MODEL; VOLUNTEER;

ADULT; ALLELES; BAYES THEOREM; BIOLOGICAL AVAILABILITY; DIGOXIN; FEMALE; GENOTYPE; HUMANS; MALE; MODELS, STATISTICAL; NONLINEAR DYNAMICS; P-GLYCOPROTEIN; PHARMACOGENETICS; POLYMORPHISM, GENETIC; SEX FACTORS; STOCHASTIC PROCESSES; TISSUE DISTRIBUTION;

EID: 34147130779     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-007-0269-5     Document Type: Article

References (42)

1. Anglicheau D, Verstuyft C, Laurent-Puig P, Becquemont L, Schlageter MH, Cassinat B et al (2003) Association of the Multidrug Resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J Am Soc Nephrol 14:1889-1896
2. Becquemont L, Verstuyft C, Kerb R, Brinkmann U, Lebot M, Jaillon P et al (2001) Effect of grapefruit juice on digoxin pharmacokinetics in humans. Clin Pharmacol Ther 70:311-316
3. Benjamini Y, Hochberg B (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Stat Soc B 57:289-300
4. Bonhomme-Faivre L, Devocelle A, Saliba F, Chatled S, Maccario J, Farinotti R et al (2004) MDR-1 C3435T polymorphism influences cyclosporine A dose requirement in liver-transplant recipients. Transplantation 78:21-25
5. Brendel K, Comets E, Laffont C, Laveille C, Mentré F (2006) Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide. Pharm Res 23:2036-2049
6. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P et al (2002) Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99:754-758
7. Comets E, Mentré F (2001) Evaluation of tests based on individual versus population modelling to compare dissolution curves. J Biopharm Stat 11:107-123
8. Delyon B, Lavielle M, Moulines E (1999) Convergence of a stochastic approximation version of the EM algorithm. Ann Stat 27:94-128
9. Dempster A, Laird N, Rubin D (1977) Maximum likelihood from incomplete data via the EM algorithm. J Roy Stat Soc B 39:1-38
10. Diasio R, Johnson M (2000) The role of pharmacogenetics and pharmacogenomics in cancer chemotherapy with 5-fluorouracil. Pharmacology 61:199-203
11. Englund G, Hallberg P, Artursson P, Michaelsson K, Melhus H (2004) Association between the number of coadministered Pglycoprotein inhibitors and serum digoxin levels in patients on therapeutic drug monitoring. BMC Med 2:8
12. Ensom M, Chang T, Patel P (2001) Pharmacogenetics: the therapeutic drug monitoring of the future? Clin Pharmacokinet 40:783-802
13. Fabris M, Tolusso B, Di Poi E, Assaloni R, Sinigaglia L, Ferraccioli G (2002) Tumor necrosis factor-alpha receptor II polymorphism in patients from southern Europe with mild-moderate and severe rheumatoid arthritis. J Rheumatol 29:1847-1850
14. Girard P, Mentré F (2005) A comparison of estimation methods in nonlinear mixed effects models using a blind analysis. Population Approach Group in Europe Annual Meeting (Abstract 384). Available at: http://www.page-meeting. org./
15. Hornestam B, Jerling M, Karlsson MO, Held P (2003) Intravenously administered digoxin in patients with acute atrial fibrillation: a population pharmacokinetic/pharmacodynamic analysis based on the Digitalis in Acute Atrial Fibrillation trial. Eur J Clin Pharmacol 58:747-755
16. Johne A, Kopke K, Gerloff T, Mai I, Rietbrock S, Meisel C et al (2002) Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin Pharmacol Ther 72:584-594
17. Jonsson E, Karlsson M (1998) Automated covariate model building with NONMEM. Pharm Res 15:1463-1468
18. Kass R, Raftery A (1995) Bayes factors. J Am Stat Assoc 90:773-795
19. Kirchheiner J, Heesch C, Bauer S, Meisel C, Seringer A, Goldammer M et al (2004) Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 76:302-312
20. Kuhn E, Lavielle M (2005) Maximum likelihood estimation in nonlinear mixed effects models. Computer Stat Data Anal 49:1020-1038
21. Lavielle M, Mentré F (2007) Estimation of population pharmacokinetic parameters of saquinavir in HIV patients with the MONOLIX software. J Pharmacokinet Pharmacodyn (in press)
22. Ludden T, Beal S, Sheiner L (1994) Comparison of the Akaike Information Criterion, the Schwarz criterion and the F test as guides to model selection. J Pharmacokinet Biopharm 22:431-445
23. Maitre P, Buhrer M, Thomson D, Stanski D (1991) A three-step approach combining Bayesian regression and NONMEM population analysis: application to midazolam. J Pharmacokinet Biopharm 19:377-378
24. Mandema J, Verotta D, Sheiner L (1992) Building population pharmacokinetic-pharmacodynamic models. I. Models for covariate effects. J Pharmacokin Biopharm 20:511-528
25. McLeod H, Yu J (2003) Cancer pharmacogenomics: SNPs, chips, and the individual patient. Cancer Invest 21:630-640
26. Panhard X, Mentré F (2005) Evaluation by simulation of tests based on non-linear mixed-effects models in pharmacokinetic interaction and bioequivalence cross-over trials. Stat Med 10:1509-1524
27. Pinheiro J, Bates D (2000) Mixed-effects models in S and SPLUS. Springer, New York
28. R Development Core Team (2004) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria
29. Raftery A (1996) Markov chain Monte Carlo in practice. Chapman & Hall, London
30. Ragueneau I, Poirier J, Radembino N, Sao A, Funck-Brentano C, Jaillon P (1999) Pharmacokinetic and pharmacodynamic drug interactions between digoxin and macrogol. Br J Clin Pharmacol 48:453-456
31. Robert C, Casella G (1999) Monte Carlo statistical methods. Springer, New York
32. Samson A, Lavielle M, Mentré F (2006) Extension of the SAEM algorithm to left-censored data in nonlinear mixed-effects model: application to HIV dynamics model. Computer Stat Data Anal 51:1562-1574
33. Samson A, Mentré F, Lavielle M (2005) Using SAEM, a new maximum likelihood estimation method in nolinear mixed-effects models, for comparison of longitudinal responses. In: 5th Int Meet Stat Methods in Biopharmacy. Paris, France
34. Sheiner L, Beal S (1998) NONMEM version 5.1. University of California, NONMEM Project Group, San Francisco
35. Simes R (1986) An improved Bonferroni procedure for multiple tests of significance. Biometrika 73:751-754
36. Spiegelhalter DJ, Thomas A, Best NG (2000) WinBUGS version 1.3 user manual. Imperial College, London, United Kingdom
37. Verstuyft C, Morin S, Yang J, Loriot MA, Barbu V, Kerb R et al (2003) A new, rapid and robust genotyping method for CYP2C9 and MDR1. Ann Biol Clin (Paris) 61:305-309
38. Verstuyft C, Schwab M, Schaeffeler E, Kerb R, Brinkmann U, Jaillon P et al (2003) Digoxin pharmacokinetics and MDR1 genetic polymorphisms. Eur J Clin Pharmacol 58:809-812
39. Verstuyft C, Strabach S, El Morabet H, Kerb R, Brinkmann U, Dubert L et al (2003) Dipyridamole enhances digoxin bioavailability via P-glycoprotein inhibition. Clin Pharmacol Ther 73:51-60
40. Wählby U, Bouw M, Niclas Jonsson E, Karlsson M (2002) Assessment of type I error rates for the statistical sub-model in NONMEM. J Pharmacokinet Pharmacodyn 29:251-269
41. Wählby U, Niclas Jonsson E, Karlsson M (2002) Comparison of stepwise covariate model building strategies in population pharmacokinetic- pharmacodynamic analysis. AAPS PharmSci 4:E27
42. Yang Y (2005) Can the strengths of AIC and BIC be shared? A conflict between model identification and regression estimation. Biometrika 92:937-950